Pricing Log in Create free account

Definium Therapeutics, Inc. (DFTX) vs Scholar Rock Holding Corporation (SRRK)

Definium Therapeutics, Inc. and Scholar Rock Holding Corporation are both Biotechnology companies. Definium Therapeutics, Inc. and Scholar Rock Holding Corporation are of similar size ($5.0B and $4.6B). Across the 9 metrics below, Definium Therapeutics, Inc. leads on 5 and Scholar Rock Holding Corporation on 4.

Valuation

Metric DFTX SRRK Biotechnology median
P/E n/m n/m 8.50
P/S n/m 110.04 9.71
P/B 3.87 20.51 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 103.78 9.21
Earnings yield (10.69%) (8.66%) (33.15%)
Free cash flow yield (4.73%) (5.71%) (25.50%)

Profitability

Metric DFTX SRRK Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (64.09%) (167.77%) (56.36%)
Return on assets (51.35%) (94.63%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DFTX SRRK Biotechnology median
Revenue growth (TTM) — 213.65% 6.02%
EPS growth (last fiscal year) (33.77%) (33.20%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DFTX SRRK Biotechnology median
Debt to equity 0.04 0.77 0.00
Current ratio 6.95 7.02 4.72
Net debt to EBITDA 2.21 0.69 0.96

Dividend

Metric DFTX SRRK Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DFTX SRRK Biotechnology median
Market cap 4.60b 4.95b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack